Abemaciclib

SAN DIEGO — The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than reported in prior clinical trials, according to study results.

In this video, Alexander Chehrazi-Raffle, MD, discusses the results of the CYCLONE 2 study into metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.

CHICAGO — The addition of abemaciclib to fulvestrant extended PFS for patients with advanced breast cancer whose disease progressed on prior cyclin-dependent kinase 4/6 inhibitor therapy, according to data presented at ASCO Annual Meeting.

CHICAGO — First-line use of cyclin-dependent kinase 4/6 inhibitors did not confer significant benefit vs. second-line use when added to endocrine therapy for women with hormone receptor-positive, HER2-negative, advanced breast cancer.

The FDA expanded the approval of abemaciclib, combined with endocrine therapy, as adjuvant treatment for adults with hormone receptor-positive, HER2-negative, node-positive early breast cancer.

This year’s San Antonio Breast Cancer Symposium spotlighted practice-changing research in several subtypes.

SAN ANTONIO — The benefit of adding abemaciclib to adjuvant endocrine therapy for certain patients with high-risk breast cancer deepened with time, according to randomized phase 3 results presented at San Antonio Breast Cancer Symposium.

In this video, Erica L. Mayer, MD, MPH, discusses important takeaways from breast cancer sessions at this year’s European Society for Medical Oncology Congress.

In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more.

Breast Cancer Awareness Month is observed every October.